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ABSTRACT
Metastatic epithelial ovarian cancer (EOC) cells can form multicellular spheroids 
while in suspension and disperse directly throughout the peritoneum to seed secondary 
lesions. There is growing evidence that EOC spheroids are key mediators of metastasis, 
and they use specific intracellular signalling pathways to control cancer cell growth 
and metabolism for increased survival. Our laboratory discovered that AKT signalling 
is reduced during spheroid formation leading to cellular quiescence and autophagy, 
and these may be defining features of tumour cell dormancy. To further define the 
phenotype of EOC spheroids, we have initiated studies of the Liver kinase B1 (LKB1)-5′-
AMP-activated protein kinase (AMPK) pathway as a master controller of the metabolic 
stress response. We demonstrate that activity of AMPK and its upstream kinase LKB1 are 
increased in quiescent EOC spheroids as compared with proliferating adherent EOC cells. 
We also show elevated AMPK activity in spheroids isolated directly from patient ascites. 
Functional studies reveal that treatment with the AMP mimetic AICAR or allosteric 
AMPK activator A-769662 led to a cytostatic response in proliferative adherent ovarian 
cancer cells, but they fail to elicit an effect in spheroids. Targeted knockdown of STK11 
by RNAi to reduce LKB1 expression led to reduced viability and increased sensitivity to 
carboplatin treatment in spheroids only, a phenomenon which was AMPK-independent. 
Thus, our results demonstrate a direct impact of altered LKB1-AMPK signalling function 
in EOC. In addition, this is the first evidence in cancer cells demonstrating a pro-survival 
function for LKB1, a kinase traditionally thought to act as a tumour suppressor.
INTRODUCTION
Ovarian cancer is the most lethal gynecologic 
malignancy in the developed world, and the overall survival 
for women diagnosed with late-stage disease has remained 
largely unchanged for more than 25 years [1, 2]. Models 
that can be used to uncover the molecular events important 
for disease dissemination are crucial since the majority of 
women with ovarian cancer (over 75%) are diagnosed at 
advanced stage [3]. Intraperitoneal implants identified in 
these patients with advanced-stage disease are the result 
of single cells and multicellular aggregates, or spheroids, 
that adhere to the mesothelial lining of various abdominal 
organs to establish secondary lesions [4–6]. This is often 
accompanied by accumulation of ascites fluid within the 
peritoneal cavity, where cells in suspension are exposed 
Oncotarget22425www.impactjournals.com/oncotarget
to a unique set of microenvironmental cues, allowing this 
population of cells to form secondary metastases [7]. These 
non-adherent metastatic cells provide unique therapeutic 
challenges for treatment of ovarian cancer.
The biological significance and clinical relevance 
of multicellular spheroids has been documented in many 
different tumour types [8–14]. It is well accepted that 
spheroids more closely mimic the cell-cell, cell-matrix 
interactions, metabolic gradients, cellular viability and 
differentiation of malignant cells within a solid tumour 
than do conventional monolayer cultures [15]. We 
have shown that ascites-derived ovarian cancer cells 
in suspension form dormant multicellular aggregates 
characterized by quiescence and decreased Akt activity 
[16]. These dormant cells are subsequently able to re-
enter the cell cycle and proliferate when they reach an 
adherent substratum. Ovarian cancer cells that are able 
to resist anoikis, and survive within peritoneal or ascitic 
fluid, have likely adapted key survival pathways to 
meet the nutrient and energy demands of this particular 
microenvironment.
A fundamental requirement of all cells is the 
ability to respond to various forms of metabolic stress 
and balance ATP consumption and generation. Under 
conditions where nutrients are low, AMP-activated 
protein kinase (AMPK) acts as a metabolic checkpoint 
by activating catabolic processes and inhibiting anabolic 
metabolism [17, 18]. It has been suggested that AMPK 
may function as a context-dependent tumour suppressor 
or oncogene [17]. Modest activation of AMPK may be 
cell protective, but prolonged or enhanced activation 
can be detrimental and result in growth arrest or cell 
death. AMPK is a heterotrimeric complex containing a 
catalytic α-subunit and two regulatory subunits, β and 
γ. When intracellular ATP levels are low, AMP or ADP 
directly bind to the γ regulatory subunits. This causes a 
conformation change in the complex that allows AMPK 
to be phosphorylated at threonine 172 on the α subunit 
[18]. The primary kinase responsible for phosphorylation 
at this site is Liver kinase B1 (LKB1) [19, 20]. LKB1 
is encoded by STK11, which is commonly regarded 
as a tumour suppressor gene and is mutated in the 
rare hereditary autosomal dominant Peutz-Jeghers 
Syndrome. These patients experience benign intestinal 
hamartomatous polyps and have an increased risk of 
developing malignant tumours, including ovarian cancer 
[21]. In fact, recent studies have reported that loss of 
LKB1 expression may be an early event in high-grade 
serous ovarian cancer development [22, 23]. Despite this, 
solid evidence for STK11 loss-of-function mutations has 
been identified in relatively few sporadic cancers.
Previous studies have shown that metabolic stress 
is induced when normal epithelial cells lose attachment to 
the extracellular matrix, resulting in a decreased ATP:ADP 
ratio and subsequent activation of AMPK [24, 25]. However, 
this suspension-induced AMPK activation has yet to 
be examined in tumour spheroids. In our study, we use a 
metastatic disease-relevant spheroid model to interrogate 
the function of the LKB1-AMPK pathway in ovarian cancer 
cells. Our results clearly demonstrate that LKB1 expression 
is maintained in nearly all ovarian cancer cells. Most 
importantly, we show that LKB1 and AMPK serve distinct 
functions in ovarian cancer cells and spheroids to regulate 
cell proliferation, cell survival and chemotherapy-resistance.
RESULTS
LKB1 and AMPKα expression and activity in 
ovarian tumours
Activity of the LKB1-AMPK signalling pathway is 
commonly thought to be tumour suppressive [26]. Multiple 
studies have suggested that single allelic inactivation of 
the STK11 gene encoding LKB1 is sufficient to promote 
tumorigenesis, while other data suggests that biallelic loss 
may be required [27–30]. In order to examine the status 
of STK11 (LKB1) and PRKAA1 (AMPKα1) in serous 
ovarian tumours, we analyzed the gene copy number 
and reverse phase protein array (RPPA) data available 
from The Cancer Genome Atlas (TCGA) datasets using 
cBioPortal [31, 32]. The STK11 gene exhibited copy-
number alteration in 93% of 311 samples, with the 
majority (84%) comprising heterozygous deletion of the 
gene (Figure 1A). This single allelic loss correlated with 
decreased protein expression compared to samples with 
normal copy-number, and a positive correlation between 
STK11 copy-number and LKB1 protein expression when 
we performed regression analysis on log2-transformed 
copy-number data (Figure 1B). When we examined 
LKB1 expression in ovarian tumour metastasis samples 
directly, however, we consistently observed detectable 
levels of phosphorylated and total LKB1 (Figure 1C). 
Therefore, despite single allele loss of STK11, LKB1 
protein expression is maintained in metastatic ovarian 
cancer cells and may in fact serve an important function 
in late-stage disease.
AMPK has been described in many instances to serve 
as a tumour suppressor despite the lack of genetic evidence 
to demonstrate a loss of AMPK function in cancer [17]. 
Analysis of the PRKAA1 gene (encoding AMPKα1) in TCGA 
data revealed copy-number alteration in 50% of serous 
ovarian tumours, with the majority (36%) comprising copy-
number gain (Figure 1A). To determine whether PRKAA1 
copy-number correlated with protein expression, we plotted 
RPPA data against copy-number calls for both p-AMPKα 
(T172) and AMPKα. This demonstrated a significant increase 
in both phosphorylated and total AMPKα in samples with 
copy-number gain with a positive correlation between copy-
number and AMPKα protein expression (Figure 1B). We also 
verified AMPKα expression and activity in lysates generated 
from ovarian tumour specimens directly (Figure 1C).
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Figure 1: LKB1 and AMPKα expression in ovarian tumours. A. Oncoprint analysis of copy number at the STK11 and PRKAA1 
gene loci are depicted for 311 ovarian serous cystadenocarcinoma tumours obtained using the provisional TCGA dataset from cBioPortal. 
Amplification (red), copy number gain (pink), heterozygous deletion (light blue) and homozygous deletion (dark blue) are shown. B. Top 
panels: LKB1, AMPKα and phospho-AMPKα (Thr172) protein expression data from 397 serous ovarian tumours as determined by RPPA 
analysis and obtained from the TCGA dataset. Protein expression z-score is plotted against copy number. One-way ANOVA with Tukey’s 
Multiple Comparison Test was performed (*, p < 0.05; ***, p < 0.001). Bottom panels: LKB1, AMPKα and p-AMPKα protein expression 
data was log2-transformed and plotted against log2-transformed gene copy number values. Pearson’s r correlation, goodness-of-fit R
2, and 
p values are reported. C. Lysates were generated from flash-frozen ovarian tumour samples from seven patients and immunoblot was 
performed to examine p-LKB1 (S428), LKB1, p- AMPK α (T172), and AMPKα expression in these samples.
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Spheroids in patient ascites exhibit enhanced 
AMPK activity
We have previously demonstrated that ovarian cancer 
cells form multicellular aggregates, or spheroids, and 
enter a dormant state, a process characterized by reduced 
proliferation and induced autophagy controlled in part by 
decreased AKT activity [16, 33]. Herein, we postulate that 
LKB1-AMPK signalling is another pathway mediating 
spheroid-induced dormancy due to its central function in 
responding to energy stress, such as nutrient deprivation 
and hypoxia [34], which are processes known to occur in 
these 3D structures [10, 15]. In order to evaluate this, we 
analyzed p-AMPK in spheroids filtered directly from patient 
ascites by western blot and immunofluorescence. Ascites 
spheroids from a number of different patient samples 
(n = 5) revealed a significant increase in p-AMPK in 
spheroids compared to matched adherent primary samples 
(passage-0) from the same patient (Figure 2A). Additionally, 
immunofluorescence revealed an intense signal for 
phosphorylated AMPKα (p-AMPKα) in the cytoplasm of 
native ascites-derived spheroids as compared with little to 
no detectable p-AMPK in matched adherent primary EOC 
cells (Figure 2B). These data indicate that AMPK activity 
is enhanced in malignant EOC cells in spheroids, which are 
the conduits of metastasis within ascites fluid.
LKB1-AMPK signalling is activated during 
ovarian cancer spheroid formation
Following our observation that AMPK activity is 
enhanced in native ascites spheroids, we sought to further 
investigate the regulation of this phenomenon using 
spheroids formed in vitro. The majority of ovarian cancer 
cell lines grown as adherent proliferating cells in culture 
exhibit low to undetectable levels of phosphorylated LKB1 
(p-LKB1) (S428) and p-AMPK α (T172) (Figure 3A, 3B; 
Supplementary Figure S1). In contrast, western blot analysis 
revealed a significant increase in p-LKB1 and p-AMPK 
expression associated with spheroid formation when 
compared with adherent cells (Figure 3A, 3B). Although 
LKB1 phosphorylation does not affect its catalytic activity, 
phosphorylation at S428 has been shown to be important 
for the tumour suppressive functions of LKB1 [35, 36]. 
LKB1 can be localized to either the nucleus or cytoplasm, 
and it is the cytoplasmic pool of LKB1 that contributes to 
the tumour suppressive function of this kinase [26]. Thus, 
we performed cellular fractionation and immunoblotting to 
determine LKB1 localization and demonstrate that LKB1 is 
found in the cytoplasm in both adherent and spheroid cells 
(Supplementary Figure S2).
Since the LKB1-AMPK signalling pathway has 
been identified as a key negative regulator of mTORC1 
signalling, we used this pathway as a downstream 
readout for the ability of LKB1-AMPK to rewire cellular 
metabolism in spheroids. Immunoblot performed on 
spheroids from cell lines and ascites-derived cells revealed 
a significant decrease in mTORC1 activity as determined 
by p70S6K1 phosphorylation (Figure 3C). This result 
implies that activation of LKB1-AMPK signalling in 
spheroids with the downstream inactivation of mTORC1 
would lead to a significant decrease in cellular anabolic 
metabolism. To assess whether the overall energy 
metabolism of spheroid cells was also reduced, we 
determined levels of intracellular ATP in ovarian cancer 
cells in adherent and spheroid culture. Indeed, ATP levels 
were significantly lower in spheroids generated using 
three ovarian cancer cell lines compared to their adherent 
counterparts (Figure 3D). Taken together, our results 
demonstrate that LKB1-AMPK signalling appears to be 
intact and active in metastatic epithelial ovarian cancer, 
and that the overall metabolic state is altered in ovarian 
cancer spheroids with a concomitant response of activated 
LKB1-AMPK signalling.
Forced AMPK activity in proliferating ovarian 
cancer cells induces cytostasis
To further investigate a potential causal relationship 
between active LKB1-AMPK signalling and the dormancy 
phenotype of ovarian cancer spheroids, we first sought to 
determine the effect of enforced LKB1-AMPK signalling 
on proliferating ovarian cancer cells. It has been previously 
demonstrated that treatment of ovarian cancer cells with 
AMP mimetic AICAR results in increased AMPK activity 
and decreased viability of adherent cells [37, 38]. Treatment 
of ovarian cancer cells with 1 mM AICAR led to a robust 
phosphorylation of AMPKα (Figure 4A). We also tested a 
more specific allosteric AMPK activator, A-769662, which 
stimulates AMPK directly without affecting the kinase 
domain [39]. Treatment of ovarian cancer cells with 100 
μM of A-769662 resulted in activation of AMPK, indicated 
by increased phosphorylation of the downstream AMPK 
substrate acetyl-CoA carboxylase (ACC) (Figure 4B). We 
then assessed the effect of extended AMPK activation on 
the growth and viability of various ovarian cancer cell 
lines and ascites-derived cells. AICAR treatment decreased 
the viability of adherent cells (4/6 cell lines) after 3 d of 
treatment (Figure 4C), and this effect was not as robust in 
spheroids (2/6 cell lines). Treatment with A-769662 resulted 
in only a modest decrease in viable cell number in adherent-
cultured cells (2/6 cell lines), and no effect on ovarian 
cancer spheroids (Figure 4D). We confirmed that both 
AICAR and A-769662 resulted in similar AMPK activation 
in treated adherent cells and spheroids (Supplementary 
Figure S3). The same differential effect between adherent 
cells and spheroids was observed by AICAR treatment of 
ascites-derived cells (Supplementary Figure S4A). When 
spheroids are allowed to reattach to tissue culture plastic, 
cells disperse based on the combination of cell proliferation 
and motility. AICAR treatment of spheroids generated 
from ascites-derived cells during reattachment led to a 
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significant reduction in dispersion area (Supplementary 
Figure S4B). Since AICAR treatment of ovarian cancer 
cells in scratch assays exhibited no effect on cell motility 
over 24 hours (data not shown), this demonstrates further 
that forced pharmacologic AMPK activation is detrimental 
to proliferating ovarian cancer cells.
Figure 2: Native ascites spheroids have enhanced phosphorylated AMPK compared to adherent cells. A. Representative 
immunoblot of p-AMPKα (Thr172) and total AMPKα in lysates isolated from native patient ascites-derived EOC spheroids as compared 
with passage-0 cultured cells. B. Densitometric analysis of immunoblot results from five independent patient ascites samples comparing 
p-AMPKα to total AMPKα. Data represents the mean ± SEM and Student’s t-test (*, p < 0.05). C. Immunofluorescence analysis of 
p-AMPKα (green) in native ascites-derived spheroids analysis compared with matched primary adherent cells from the same patient (EOC 
169). DAPI staining (blue) of nuclei is shown. Scale bar: 10 μm.
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Following the observation that both AICAR and 
A-769662 reduce the proportion of viable ovarian cancer 
cells in proliferating adherent culture, we tested these 
agents on the clonogenic capacity of several ovarian cancer 
cell lines. Hey, OVCAR5 and OVCAR8 cells displayed 
reduced colony formation due to AICAR and A-769662 
treatment (Figure 4E). Flow cytometry was performed to 
assess whether forced AMPK activation affected ovarian 
cancer cell cycle. Both compounds resulted in a decreased 
proportion of ovarian cancer cells in the S-phase of the 
cell cycle as early after 24 h of treatment, and in most 
instances with a respective increase in cells in G0/G1 and 
G2 (Figure 4F). We also assessed apoptosis in AICAR- 
and A-769662-treated ovarian cancer cells, and there 
was no effect of these agents on inducing programmed 
cell death to reduce viable cell number (data not shown). 
Taken together, these results suggest that forced AMPK 
activity in proliferating ovarian cancer cells acts to induce 
a cytostatic response, and may explain a function for 
the observed increase in endogenous p-AMPK in non-
proliferating EOC spheroids.
LKB1 is required for ovarian cancer cell survival 
and platinum resistance in spheroids
Given the relative insensitivity of ovarian cancer 
cells in spheroids to further activation of AMPK, we 
assessed the functional impact of attenuation of the 
Figure 3: Increased LKB1-AMPK signalling activity in ovarian cancer spheroids. A. Immunoblot analysis of OVCAR3, 
Hey and SkOV3 cell lines and ascites-derived EOC cells to determine levels of p-LKB1 (Ser428) and LKB1 expression in cultures of 
adherent cells (adh) and 3-day spheroids (sph). Densitometry was performed on immunoblot data from cell lines and ascites-derived EOC 
cells (n = 16) to quantify change in p-LKB1 expression relative to LKB1. Data is represented as mean ± SEM and Student’s t-test for 
statistical significance (*, p < 0.05). B. Immunoblot analysis of OVCAR3, Hey and SkOV3 cell lines and ascites-derived EOC cells to 
determine levels of p-AMPKα (Thr172) and AMPKα expression in adherent cells (adh) and spheroids (sph). Densitometry was performed 
on immunoblot data from cell lines and ascites-derived EOC cells (n = 14) to quantify change in p-AMPKα expression relative to AMPKα. 
Data is represented as mean ± SEM and Student’s t-test for statistical significance (*, p < 0.05). C. Immunoblot analysis of Hey and 
SkOV3 cell lines and ascites-derived EOC cells to determine levels of p-p70S6K (Thr389) and p70S6K as a measure of mTORC1 activity. 
D. Quantification of intracellular ATP levels in SkOV3, Hey and OVCAR3 cell lines using luminescence-based ATP assay CellTiter 
Glo® cultured as adherent cells (adh) or spheroids (sph). Luminescence values were normalized to total protein in each sample. Data is 
represented as mean ± SEM and Student’s t-test for statistical significance (***, p < 0.001).
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Figure 4: Stimulation of AMPK activity in proliferating ovarian cancer cells reduces growth and colony forming 
potential. A. Immunoblot analysis of p-AMPKα (Thr172) and AMPKα expression in Hey cells treated for 24 h with 0.5, 1 or 2 mM 
AICAR. B. Immunoblot analysis of p-ACC (Ser79) and ACC expression in Hey cells treated for 24 h with 25, 50 or 100 μM A-769662. C. 
Cell viability was determined following 3 d of AICAR (1 mM) treatment (black bar), or DMSO control (white bar) of six ovarian cancer 
cell lines cultured as adherent cells and spheroids. Data is represented as mean ± SEM and Student’s t-test for statistical significance (*, p 
< 0.05). D. Cell viability was determined following 3 d of A-769662 (100 μM) treatment (black bar), or DMSO control (white bar) of six 
ovarian cancer cell lines cultured as adherent cells and spheroids. Data is represented as mean ± SEM and Student’s t-test for statistical 
significance (*, p < 0.05). E. Clonogenic assays were performed by seeding ovarian cancer cell lines (1, 000 cells per well of 6-well 
dish) treating with 1 mM AICAR, 100 μM A-769662, or DMSO control for 3 d, followed by growth recovery in complete media. Data is 
represented as mean ± SEM and one-way ANOVA with Tukey’s Multiple Comparison test (*, p < 0.05; **, p < 0.01; ***, p < 0.001). F. 
Cell cycle analysis was performed by flow cytometry using BrdU and PI staining of OVCAR3, OVCAR8 and SkOV3 cells following 24 
h of treatment with either 1 mM AICAR or 100 μM A-769662 (n = 2 for each cell line). Data is represented as proportion of cells in G0/
G1, S and G2/M phases of the cell cycle. Data is represented as mean ± SEM and one-way ANOVA with Tukey’s Multiple Comparison test 
(*, p < 0.05; **, p < 0.01; ***, p < 0.001).
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LKB1/AMPK pathway in spheroids. We transfected 
SkOV3, OVCAR8 and iOvCa147-E2 ovarian cancer cell 
lines with pooled siRNAs against PRKAA1 (AMPKα1) 
and STK11 (LKB1). Effective knockdown of STK11 
and PRKAA1 was achieved in both adherent monolayer 
cells and spheroids (Figure 5A). Cells in adherent culture 
were not sensitive to knockdown of either PRKAA1 or 
STK11 with respect to cell viability, most likely since 
these cells are proliferating and have low LKB1-AMPK 
signalling activity (Supplementary Figure S1). In marked 
Figure 5: LKB1 expression is required to maintain cell viability and promote chemoresistance of ovarian cancer 
spheroids. A. Immunoblot analysis of LKB1 and AMPKα expression in ovarian cancer cells transfected with STK11 and PRKAA1 siRNA 
pools, or control siRNA (siNT). Expression was determined 72 h after transfection in adherent cells, or 72 h after cells were seeded to 
form spheroids. B. Cell viability was determined after 72 h using CellTiter-Glo® assay on siRNA-transfected SkOV3, OVCAR8 and 
iOvCa147-E2 cell lines cultured as adherent cells or spheroids. Data is represented as mean ± SEM and one-way ANOVA with Tukey’s 
Multiple Comparison test (*, p < 0.05; ***, p < 0.001). C. The experiment was performed as in (B), but where SkOV3 and OVCAR8 cell 
lines were treated with 50 μM carboplatin at 72 h post-transfection in adherent culture or at the time of seeding to 24-well ULA cluster plate 
to form spheroids. Cell viability was determined after 72 h using CellTiter-Glo® assay. Data is represented as mean ± SEM and one-way 
ANOVA with Tukey’s Multiple Comparison test (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
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contrast, loss of LKB1 expression significantly reduced 
cell viability in spheroids, whereas PRKAA1 knockdown 
had little to no effect (Figure 5B). Performing analogous 
experiments in patient ascites-derived EOC cells, we 
observed a similar effect of reduced viability in spheroids 
due to STK11 knockdown (Supplementary Figure S5).
Platinum-based chemotherapy is the standard for first-
line treatment of metastatic epithelial ovarian cancer, yet 
the majority of patients will eventually recur with platinum-
resistant disease [40]. Ovarian cancer spheroids are largely 
resistant to platinum treatment, likely due to their reduced 
proliferative state [16, 41]. To assess whether loss of 
LKB1-AMPK signalling can affect ovarian cancer spheroid 
sensitivity to platinum agents, adherent cell and spheroids 
transfected with STK11 or PRKAA1 siRNA were treated 
subsequently with carboplatin. We observed a dramatic 
reduction in cell viability in ovarian cancer spheroids when 
loss of LKB1 was combined with carboplatin treatment, 
whereas this effect was not seen is spheroids with PRKAA1 
knockdown, or in adherent cells under all treatment 
conditions (Figure 5C). These final results point to a critical 
role for LKB1 signalling in maintaining cell viability and 
achieving chemo-resistance in dormant ovarian cancer 
spheroids largely in an AMPK-independent manner.
DISCUSSION
The distinct mode of metastatic spread whereby 
EOC cells transit the peritoneal cavity in suspension 
presents unique therapeutic challenges for treatment of 
advanced-stage ovarian cancer [42, 43]. Characterization 
of this unique population of non-adherent cells will 
provide insights into novel targets for treatment of this 
deadly disease. Our laboratory and others have shown 
that ovarian cancer cells in suspension have a propensity 
to aggregate and form non-proliferating cell clusters 
or spheroids [16, 44]. Further to this observation, we 
report here that cells in dormant EOC spheroids have 
reduced metabolic activity and induce the LKB1-AMPK 
metabolic stress response pathway. AMPK activity is 
enhanced in quiescent ovarian cancer spheroids, and in 
a reciprocal fashion, pharmacologic activation of AMPK 
in proliferating, adherent ovarian cancer cells leads to 
cytostasis. We have also uncovered a novel phenomenon 
where LKB1 is required for ovarian cancer cell survival 
and resistance to chemotherapy treatment in spheroids, 
whereas AMPK, the primary downstream substrate of 
LKB1, is dispensable. This implies that LKB1 utilizes 
an AMPK-independent signal to promote cell survival 
in metastatic ovarian cancer spheroid cells. In addition, 
ours is the first study to demonstrate the maintenance of 
LKB1 expression in ovarian cancer cells and its potential 
functional requirement during metastasis.
Expansive tumour growth is typically dependent 
on over-proliferative malignant cells that lack the normal 
response to induce protective growth arrest [45]. Under 
nutrient-rich conditions, proliferative cancer cells should 
have low or absent levels of active AMPK signalling. 
Indeed, we show that expression of phosphorylated 
AMPKα is marginal in the majority of adherent 
proliferating EOC cells. AMPK activity, however, 
is significantly elevated upon spheroid formation in 
line with the cellular quiescent phenotype of these 
structures [16]. AICAR and A-769662 both induce a 
potent cytostatic response in proliferating adherent cells 
without any significant cell death due to induction of 
apoptosis; and further activation of AMPK using these 
agents in spheroids has little impact on proliferation or 
viability. A recent report demonstrated that the growth-
suppressive effects of AICAR are independent of AMPK 
in glioma cells [46]. Thus, the decrease in ovarian 
cancer cell proliferation observed in ovarian cancer cells 
treated with AICAR may occur via AMPK-independent 
mechanisms. However, a tumour suppressive-like 
activity for AMPK has been observed in ovarian cancer 
cells via the overexpression of the β1-subunit of AMPK 
[47]. Taken together, suppressed AMPK signalling is 
likely required to sustain active ovarian tumour growth 
(Figure 6), and supports a general idea that this pathway 
possesses classical tumour suppressor function under these 
conditions. Indeed, pharmacologic activation of AMPK 
signaling in the context of gynecologic cancer treatment 
has been discussed as a possible strategy for prolonging 
disease-free interval in patients [48, 49].
It is reasonable to postulate that LKB1 function 
may possess contrasting context-specific activities during 
steps of ovarian cancer progression (Figure 6). A recent 
report of a conditional mouse model for serous ovarian 
carcinoma determined that loss of Stk11 in the context 
of Pten loss within the OSE leads to the development 
of high-grade papillary serous ovarian carcinomas [22]. 
In other cancer models, LKB1 loss-of-function has been 
shown to accelerate tumorigenesis in conjunction with 
p53 [50], Kras [51], and c-myc [52], as well. Although the 
study by Tanwar and colleagues [22] implicates loss of 
Lkb1 function in the initiation of ovarian cancer, genetic 
ablation was performed in the ovarian surface epithelium 
and not the secretory epithelium of oviduct; the secretory 
epithelium of the distal fallopian tube is now considered 
the site of origin for high-grade serous ovarian cancer [53, 
54]. Also, we present TCGA data showing the frequency of 
homozygous loss of STK11 is extremely low in high-grade 
serous ovarian tumours. Therefore, the significance of the 
results of the genetically-modified mouse model to human 
ovarian cancer is unclear. Recently, George and colleagues 
have reported reduced LKB1 protein expression in serous 
tubal intraepithelial carcinomas and high-grade serous 
ovarian tumours, again suggesting a tumour suppressor 
function [23]. In contrast, we clearly demonstrate that the 
majority of EOC solid tumour specimens, primary ascites-
derived cells and established ovarian cancer cell lines 
retain detectable LKB1 protein expression since almost 
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all serous ovarian cancers retain at least one STK11 allele. 
Interestingly, we also identified copy number gains or 
amplifications in PRKAA1, encoding AMPKα1, suggesting 
that there may be compensatory mechanisms to upregulate 
AMPK activity in late-stage ovarian tumours harbouring 
reduced LKB1 in order to maintain a functional pathway 
for tumour cell survival during metastasis. Our data 
imply that although heterozygous loss of STK11 with 
reduction in LKB1 expression may act to predispose to 
ovarian cancer initiation, maintenance of functional LKB1 
signalling is likely essential during metastatic progression 
to promote cell survival in spheroids and fuel recurrence 
of chemo-resistant ovarian cancer (Figure 6).
LKB1-AMPK signalling represents an immediate 
response to metabolic stress and reduced energy 
supply to downregulate anabolic metabolism and shunt 
pathways to utilize alternative energy substrates [17, 
55]. It has been shown in other cell systems that LKB1-
AMPK signalling is an important mediator of protecting 
detached epithelial cells from anoikis [24, 25]. We show 
that targeted knockdown of STK11 yielded a significant 
reduction in ovarian cancer spheroid cell viability, yet 
there was no effect when AMPKα1 expression was 
reduced. We confirmed that there was no compensatory 
effect of AMPKα2 expression in PRKAA1-knockdown 
spheroid cells that could explain this lack of effect, nor 
did PRKAA2 siRNA elicit any change in total AMPKα 
expression in ovarian cancer cell lines (data not shown). 
This implies that LKB1 plays an important role in 
mediating anoikis-resistance in EOC spheroids, and 
perhaps other characteristics of the dormant phenotype of 
these structures, independent of AMPK.
AMPK is the most studied downstream target 
of LKB1. However, LKB1 has been called a ‘master 
kinase’ given its ability to phosphorylate at least 12 other 
downstream proteins, referred to as AMPK-related kinases 
(ARKs) [56]. Perhaps one or more of these ARKs are 
critical downstream mediators of the LKB1-dependent 
effects on cell viability in ovarian cancer spheroids. For 
example, salt inducible kinase 2 (SIK2) is overexpressed 
in high-grade serous ovarian cancer and has been shown 
to function in cell division through its regulation of mitotic 
spindle formation by phosphorylating proteins of the 
centrosome [57]. Likewise, SIK3 has been documented 
as a putative tumour-associated antigen with expression in 
55% of ovarian cancer samples, and, like SIK2, can control 
cell cycle progression at the G1/S checkpoint [58]. Whether 
these ARKs represent AMPK-independent targets of LKB1 
signalling in EOC spheroids is unknown; as such, further 
studies are needed to determine which of the numerous 
substrates downstream from LKB1 are mediating its effects 
on maintaining cell viability in ovarian cancer spheroids.
Figure 6: Proposed divergent roles for LKB1-AMPK signalling in metastatic ovarian cancer. Ovarian cancer metastasis 
occurs via direct dissemination of primary tumour cells into the peritoneal cavity. Single cells in suspension will readily undergo detachment-
induced apoptosis, or anoikis, but the formation into multicellular aggregates called spheroids protects them from cell death. Spheroids 
possess an enhanced ability to reattach onto the serosal surfaces of peritoneal organs upon which the ovarian tumour cells make a “dormant-
to-proliferative switch” and grow to establish secondary metastases. Rapidly-expanding tumour growth (whether in the primary tumour or 
metastases) would require reduced LKB1-AMPK signalling to allow for increased cell proliferation and anabolic metabolism. Spheroids, 
on the other hand, adopt a number of pathobiological changes which we propose contribute to their dormant phenotype and facilitate 
cell survival during metastatic transit in suspension. Our new results support the role for active LKB1-AMPK signalling contributing to 
ovarian cancer cell dormancy in spheroids by reducing energy metabolism and cell proliferation, yet promote cell survival and carboplatin-
resistance in EOC spheroids.
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EOC spheroids have the capacity to harbour a 
niche of chemotherapy-resistant cells. Our data supports 
this idea, and we provide the first evidence that LKB1-
AMPK signalling may play a significant role in adaptive 
resistance mechanisms in these metastasis-promoting 
structures. Phosphorylation of both LKB1 and AMPKα 
are increased in spheroids and act to support a dormant 
non-proliferative state, which would thereby decrease 
the efficacy of standard chemotherapeutic agents. In fact, 
carboplatin and paclitaxel treatment of EOC cells increase 
phosphorylated AMPKα levels (data not shown), and 
targeted knockdown of its upstream kinase LKB1 renders 
EOC spheroids re-sensitized to carboplatin-induced cell 
death. This implies that a combination of chemotherapy 
with novel agents eliciting LKB1-AMPK pathway 
inhibition would be efficacious as an upfront approach 
to treat ovarian cancer patients with late-stage disease to 
better eradicate residual dormant micro-metastases and 
reduce chemo-resistant disease recurrence.
The general concept of tumour dormancy in cancer 
research, though provocative, is far from proven using 
experimental models. Direct empirical dissection of 
tumour dormancy mechanisms in vivo would be quite 
challenging; thus, we claim that using spheroids as a 
tractable model system to perform extensive in vitro 
investigations will facilitate the discovery of potential 
tumour dormancy mechanisms. These results could then 
be applied to complementary and direct in vivo tumour 
models and patient-derived tumour samples.
MATERIALS AND METHODS
Cell culture
SkOV3 cells were cultured using DMEM (Wisent, St. 
Bruno, Canada) with 5% fetal bovine serum (FBS; Wisent). 
Hey, HeyA8 cells, and HeyC2 cells (gift from G. Mills, MD 
Anderson) were cultured using RPMI-1640 (Wisent) with 
5% FBS. OVCAR3, OVCAR5, and OVCAR8 (purchased 
from ATCC, Manassas, VA) were cultured using RPMI-
1640 with 5% FBS. CaOV3 cells (ATCC) were cultured 
using DMEM with 10% FBS. OW-7 and 105-C cell lines 
(gift from H. Hirte, McMaster University) were grown in 
RPMI-1640 with 10% FBS. Ascites fluid was collected 
from patients, the majority of whom were diagnosed with 
advanced-stage, high-grade serous EOC (Supplementary 
Table S1), and used to establish primary cell cultures 
as previously described [59]. Cell lines iOvCa142 and 
iOvCa147-E2 were generated from ascites samples 
EOC142 and EOC147 collected at our centre.
For the majority of experiments assayed using 
spheroids, cells were seeded to 24-well ultra-low 
attachment (ULA) cluster plates (Corning) at a density 
of 5 × 104 cells per well. For protein isolation from 
spheroid cells, cells were seeded at 5 × 105 cells per well 
of a 6-well ULA cluster plate. Cells were cultured for 3 d 
in suspension to form spheroids for all experiments, unless 
otherwise specified. Native spheroids were isolated directly 
from ascites fluid by filtration through a 40 μm cell strainer 
(Becton Dickinson), washed with phosphate-buffered saline 
(PBS) into a collection tube with protein lysis buffer for 
immunoblot or embedded in OCT to prepare frozen sections 
for immunofluorescence. To compare native spheroid 
samples with matched adherent cells, cells at passage-0 were 
used. All work with patient materials has been approved by 
The University of Western Ontario Health Sciences Research 
Ethics Board (Protocol # 12668E and 16391E).
TCGA and CCLE analysis
Datasets from The Cancer Genome Atlas analysis 
of ovarian serous cystadenocarcinoma samples were 
downloaded from the University of California Santa 
Cruz Cancer Genomics Browser (https://genome-cancer.
ucsc.edu) [60] and from the Memorial Sloan-Kettering 
Cancer Center’s cBioPortal for Cancer Genomics (http://
www.cbioportal.org/) [31, 32]. Raw data was analyzed 
using the GISTIC2 method to generate gene-level copy-
number variation (CNV) estimates and downloaded 
as either thresholded copy-number calls or as log2-
transformed CNV values. Reverse-phase protein array 
data was downloaded as either natural log-transformed 
values or z-scores. Copy number and mRNA expression 
data on ovarian cancer cell lines of the Cancer Cell Line 
Encyclopedia [61] were accessed from cBioPortal.
Immunoblotting and immunofluorescence
Protein lysates were generated from cells in adherent 
and spheroid culture as previously described [62]. Protein 
lysates from solid tumour specimens were prepared by 
homogenizing flash-frozen tissue in lysis buffer [50 mM 
HEPES pH7.4, 150 mM NaCl, 10% glycerol, 1.5 mM 
MgCl2, 1 mM EGTA, 1 mM sodium orthovanadate, 10 mM 
sodium pyrophosphate, 10 mM NaF, 1% Triton X-100, 
1% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 1X 
protease inhibitor cocktail (Roche, Laval, Quebec, Canada)]. 
Antibodies used to detect p-AMPKα Thr172 (#2535), 
AMPKα (#5832), p-LKB1 Ser428 (#3482), LKB1 (#3050), 
p-p70S6K1 Thr389 (#9234), p-ACC (#3661), ACC (#3676) 
and p70S6K1 (#2708) expression by immunoblotting 
were obtained from Cell Signaling Technology (Danvers, 
MA). Anti-Tubulin antibody was obtained from Sigma 
(Mississauga, ON, Canada). AICAR was purchased from 
Caymen Chemical Company (Ann Arbor, MI) and A-769662 
from Tocris Bioscience (Bristol, UK). Immunofluorescence 
analysis was performed on cryosections of native spheroids 
that were fixed (4% formaldehyde), permeabilized 
(0.1% Triton X-100 in PBS), and blocked (5% BSA in 
0.1% Triton X-100) before incubation with p-AMPKα 
antibody (#ab51110) from Abcam® Inc. (Cambridge, MA). 
Following primary antibody incubation and PBS washes, 
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sections were incubated for 1 hour with anti-rabbit FITC 
secondary antibody (1:250 dilution; Sigma-Aldrich) and 4′, 
6-diamidino-2-phenylindole (DAPI; 1:1000) and mounted 
with Vectashield (Vector Laboratories, Burlingame CA, 
USA). Fluorescence images were captured using an 
Olympus AX70 upright microscope and ImagePro image 
capture software.
Cell viability and ATP assays
Cells were seeded to either 24-well tissue culture 
plastic or ultra-low attachment (ULA) plates at a density 
of 1 × 104 per well to form adherent cultures or 5 × 104 
per well to form spheroids, respectively. Treatment was 
initiated at time of seeding for cells in suspension while 
cells under adherent conditions were given 12 h to adhere 
before commencing treatment. At 72 h post-treatment, 
spheroids were collected, pelleted and left in media (100 μL), 
at which point CellTiter-Glo® reagent (Promega, Madison, 
WI) was added (1:1 v/v ratio). Under adherent conditions, 
cells were harvested directly in CellTiter-Glo® after 20 
min incubation. All samples were subjected to a freeze/
thaw cycle prior to analysis. Approximately 200 μL of the 
mixture was added to a white-walled 96-well microplate 
and luminescence signal was detected using a Wallac 1420 
Victor 2 spectrophotometer (Perkin-Elmer, Waltham, MA) 
and normalized to vehicle-treated cells. For measuring cell 
viability after carboplatin treatment, adherent cells and 
spheroids were treated with 50 μM carboplatin (LHSC 
Pharmacy, London, ON) and assays were performed after 72 
h as described above.
Clonogenic assays
Cells were seeded at 1 000 cells per well of a 6-well 
dish and treated with 1 mM AICAR or 100 μM A-769662 
for 72 h. Subsequently, medium was replaced with complete 
growth medium without AMPK agonists until detectable 
colonies were observed. Cells were stained with Hema-3 
and the total number of colonies was counted in each well.
Flow cytometry
Cells treated with were pulse-labeled with 
10 μM bromodeoxyuridine (BrdU; GE Healthcare, 
Buckinghamshire, UK) for 2 h. Cells were fixed in 95% 
ethanol and stored at 4°C. Cells were stained in the 
following solutions: 2N HCl/0.5% TritonX-100, 0.1M 
NaB4O4 pH 8.5, mouse anti-BrdU primary antibody (1:50; 
Becton Dickinson), anti-Mouse FITC-conjugated secondary 
antibody (1:250; Vector Laboratories, Burlingame, CA), 
and PI Staining Solution [PBS with 2% FBS, 0.25 μg/μL 
RNase, 10 μg/mL PI]. Samples were incubated at 37°C 
for 30 min, then overnight at 4°C. The following day, 
labeled cells were filtered using 40 μm cell-strainers and 
flow cytometry using a Beckman Coulter Epics XL-MCL 
(10 000 events/replicate, three replicates/experiment).
siRNA transfections
Cells were plated at a density of approximately 
1 × 105 cells per 35 mm well in antibiotic-free media, 
and transfections were performed the next day as per 
manufacturer’s protocol (Dharmacon; Thermo Fisher 
Scientific Inc., Waltham, MA). DharmaFECT1 was 
used for all cell lines and primary EOC cells, except 
DharmaFECT3 was used for SkOV3 cells. Briefly, 1 μL of 
DharmaFECT1 or 4 μL of DharmaFECT3 was combined 
with 10 nM siRNA in 1 mL of media and incubated for 
20 min; the siRNA/DharmaFECT complexes were then 
added directly to each well. Media was removed 24 h 
following transfection and replaced with antibiotic-free 
growth media. At this point, the cells were incubated 
approximately 72 h following transfection. Trypsinized 
cells were counted directly using a TC10 cell counter 
(Biorad) to determine adherent cell viability, then 
seeded at 5 × 104 cells into 24-well ULA cluster plates; 
cell viability was determined at 72 h post-seeding using 
CellTiter-Glo®. PRKAA1 (M-005027-02) and STK11 
(M-005035-02) siGENOME SMARTpool siRNAs were 
obtained from Dharmacon (Thermo Fisher Scientific Inc., 
Waltham, MA). Western blot analysis was performed on 
adherent cell lysates at 72 h post-transfection and 72 h 
post-seeding to ULA plates for spheroid lysates.
Graphing and statistical analysis
All graphs were generated and statistical analyses 
were performed using GraphPad Prism 5 (GraphPad 
Software, San Diego, CA). Data were expressed as mean 
± SEM, and statistical analyses were either Student’s t-test 
or Analysis of Variance with Tukey’s Multiple Comparison 
Test. Tests of significance were set at p < 0.05.
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